Literature DB >> 7683743

Haematopoietic growth factors and cancer therapy.

W P Sheridan1, R M Fox.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7683743     DOI： 10.5694/j.1326-5377.1993.tb121862.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN： 0025-729X            Impact factor:   7.738


× No keyword cloud information.
  3 in total

1.  Impact of ASCO guidelines for the use of hematopoietic colony stimulating factors (CSFs): survey results of fifteen Paris university hospitals.

Authors:  I Debrix; I Madelaine; N Grenet; D Roux; C Bardin; F Le Mercier; J E Fontan; O Connor; A Pointereau; P Tilleul
Journal:  Pharm World Sci       Date:  1999-12

2.  Filgrastim. A reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia.

Authors:  J E Frampton; D Faulds
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

Review 3.  Pharmacoeconomic evaluation of lenograstim. Conclusions and future directions.

Authors:  J Menzin; G Oster; V Cour-Chabernaud; D Richard
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.